Skip to main content
Log in

Benefits and Risks to Mother and Infant of Drug Treatment for Postnatal Depression

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their infants, but are hesitant to do so for fear of passing on possible harmful effects of the medication through their milk.

The focus of this article will be on highlighting and interpreting the existing literature on the benefits and risks to mother and infant of drug treatment for postnatal depression, as well as outlining treatment guidelines for the use of antidepressants in breastfeeding mothers. The article will specifically focus on the use of fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram, which are more commonly used and belong to the selective serotonin reuptake inhibitor group of antidepressants. The tricyclic and other newer antidepressant medications will also be discussed. As there are no published controlled studies on the use of antidepressants by breastfeeding women, publications of individual case reports, case series, and pharmacokinetic investigations serve as the basis for the development of treatment guidelines. Results from this growing body of literature are promising in that, with the exception of a few cases, no serious adverse events have been reported in infants exposed to antidepressant medications through breast milk. In addition nonpharmacological treatments consisting of different types of psychotherapies will be discussed. It is critical that healthcare providers evaluate each mother-infant dyad on an individual basis when faced with the decision to prescribe antidepressant medications during the postnatal period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table II
Table III

Similar content being viewed by others

References

  1. Kumar R, Robson MK. A prospective study of emotional disorders in childbearing women. Br J Psychiatry 1984; 144: 35–47

    Article  PubMed  CAS  Google Scholar 

  2. O’Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984; 93: 158–71

    Article  PubMed  Google Scholar 

  3. O’Hara MW, Swain AM. Rates and risk of postpartum depression: a meta-analysis. Int Rev Psychiatry 1996; 8: 37–54

    Article  Google Scholar 

  4. Troutman B, Cutrona C. Nonpsychotic postpartum depression among adolescent mothers. J Abnorm Psychol 1990; 99: 69–78

    Article  PubMed  CAS  Google Scholar 

  5. Llewellyn AM, Stowe ZN, Nemeroff CB. Depression during pregnancy and the puerperium. J Clin Psychiatry 1997; 58(S15): 26–32

    PubMed  Google Scholar 

  6. O’Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986; 43: 569–73

    Article  PubMed  Google Scholar 

  7. Beck CT. A meta-analysis of predictors of postpartum depression. Nurs Res 1996; 45: 297–303

    Article  PubMed  CAS  Google Scholar 

  8. Gotlib IH, Whiffen VE, Mount JH, et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989 57: 269–74

    Article  PubMed  CAS  Google Scholar 

  9. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA 1993 269: 2246–8

    Article  PubMed  CAS  Google Scholar 

  10. Chambers C, Johnson K, Dick L, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996 335: 1010–5

    Article  PubMed  CAS  Google Scholar 

  11. Nulman I, Rovet J, Stewart D, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336(4): 258–62

    Article  PubMed  CAS  Google Scholar 

  12. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998 279: 609–10

    Article  PubMed  CAS  Google Scholar 

  13. Ericson A, Källén B, Wiholm B-E. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 505–8

    Google Scholar 

  14. American Academy of Pediatrics Committee on Drugs. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 2000; 105 (4): 880–7

    Google Scholar 

  15. Beck CT. The effects of postpartum depression on maternal-infant interaction: a meta-analysis. Nursing Res 1995; 44: 298–304

    Article  CAS  Google Scholar 

  16. Beck CT. The effects of postpartum depression in child development: a meta-analysis. Arch Psychiatr Nurs 1998; 12: 12–20

    Article  PubMed  CAS  Google Scholar 

  17. Lyons-Ruth K, Wolfe R, Lyubchik A. Depression and the parenting of young children: making the case for early preventive mental health services. Harv Rev Psychiatry 2000; 8: 148–53

    PubMed  CAS  Google Scholar 

  18. Martins C, Gaffan EA. Effects of early maternal depression on patterns of infant-mother attachment: a meta-analytic investigation. J Child Psychol Psychiatry 2000; 41: 737–46

    Article  PubMed  CAS  Google Scholar 

  19. Gracious BL, Wisner KL. Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. Depress Anxiety 1997; 6: 124–8

    Article  PubMed  CAS  Google Scholar 

  20. Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993 Nov; 32(6): 1253–5

    Article  PubMed  CAS  Google Scholar 

  21. Isenberg KE. Excretion of fluoxetine in human breast milk [letter]. J Clin Psychiatry 1990; 51: 169

    PubMed  CAS  Google Scholar 

  22. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992; 89: 676–7

    PubMed  CAS  Google Scholar 

  23. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol 1996; 36: 42–7

    PubMed  CAS  Google Scholar 

  24. Birnbaum CS, Cohen LS, Bailey JW, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series [online]. Available from URL: http://www.pediatrics.org/cgi/content/full/104/1/e11 [Accessed 2000 Dec 1]

  25. Yoshida K, Smith B, Craggs M, et al. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 1998 172: 175–9

    Article  PubMed  CAS  Google Scholar 

  26. Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr 1998 Jan; 37: 41–4

    Article  CAS  Google Scholar 

  27. Kristensen JH, Ilett KF, Hackett LP, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999; 48(4): 521–7

    Article  PubMed  CAS  Google Scholar 

  28. Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine [online]. Available from URL: http://www.pediatrics.org/cgi/content/full/104/5/e61 [Accessed 2001 Dec 1]

  29. Altshuler LL, Burt VK, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995 Jun; 56(6): 243–5

    PubMed  CAS  Google Scholar 

  30. Epperson CN, Anderson GM, McDougle CJ. Sertraline and breast-feeding [letter]. N Engl J Med 1997; 336(16): 1189–90

    Article  PubMed  CAS  Google Scholar 

  31. Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997 Sep; 154(9): 1255–60

    PubMed  CAS  Google Scholar 

  32. Mammen OK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997 Mar; 58(3): 100–3

    Article  PubMed  CAS  Google Scholar 

  33. Wisner KL, Perel JM, Blumer J. Serum sertraline and ndesmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998 May; 155(5): 690–2

    PubMed  CAS  Google Scholar 

  34. Epperson N, Czarkowski KA, Ward-O’Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry 2001 Oct; 158(10): 1631–7

    Article  PubMed  CAS  Google Scholar 

  35. Öhman R, Hägg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999 Aug; 60(8): 519–23

    Article  PubMed  Google Scholar 

  36. Begg EJ, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999 48: 142–7

    Article  PubMed  CAS  Google Scholar 

  37. Misri S, Kim J, Riggs KW, et al. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000 Nov; 61(11): 828–32

    Article  PubMed  CAS  Google Scholar 

  38. Stowe ZN, Cohen LS, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000 Feb; 157(2): 185–9

    Article  PubMed  CAS  Google Scholar 

  39. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk [letter]. Br J Clin Pharmacol 1991; 31: 209

    Article  PubMed  CAS  Google Scholar 

  40. Piontek CM, Wisner KL, Perel JM, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001 Feb; 62(2): 111–3

    Article  PubMed  CAS  Google Scholar 

  41. Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psychiatry 2000; 47: 164–5

    Article  PubMed  CAS  Google Scholar 

  42. Spigset O, Carleborg L, Öhman R, et al. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997 44: 295–8

    Article  PubMed  CAS  Google Scholar 

  43. Jenson PN, Olesen OV, Bertelsen A, et al. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997; 19(2): 236–9

    Article  Google Scholar 

  44. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201–14

    Article  PubMed  CAS  Google Scholar 

  45. Suri R, Burt VK, Altshuler LL, et al. Fluvoxamine for postpartum depression [letter]. Am J Psychiatry 2001 Oct; 158(10): 1739–40

    Article  PubMed  CAS  Google Scholar 

  46. Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997 43: 225–37

    Article  PubMed  CAS  Google Scholar 

  47. Breyer-Pfaff U, Nill K, Entenmann KN, et al. Secretion of amitriptyline and metabolites into breast milk. Am J Psychiatry 1995 152: 812–3

    PubMed  CAS  Google Scholar 

  48. Pittard WB, O’Neal Jr W. Amitriptyline excretion in human milk. J Clin Psychopharmacol 1986; 6: 383–4

    Article  PubMed  Google Scholar 

  49. Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant’s serum. Am J Psychiatry 1980; 137: 855–6

    PubMed  CAS  Google Scholar 

  50. Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001 Jul; 158(7): 1001–9

    Article  PubMed  CAS  Google Scholar 

  51. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991 29: 479–84

    Article  PubMed  CAS  Google Scholar 

  52. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995 Jan; 56(1): 17–20

    PubMed  CAS  Google Scholar 

  53. Sovner R, Orsulak PJ. Excretion of imipramine and desipramine in human breast milk. Am J Psychiatry 1979; 136: 451–2

    PubMed  CAS  Google Scholar 

  54. Stancer HC, Reed KL. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant’s serum. Am J Psychiatry 1986; 143: 1597–600

    PubMed  CAS  Google Scholar 

  55. Matheson I, Pande H, Alertsen AR. Respiratory depression caused by N-desmethyldoxepin in breast milk [letter]. Lancet 1985; 2: 1124

    Article  PubMed  CAS  Google Scholar 

  56. Frey OR, Scheidt P, von Brenndorff AI. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. Ann Pharmacotherapy 1999 Jun; 33: 690–3

    Article  CAS  Google Scholar 

  57. Kemp J, Ilett KF, Booth J, et al. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmacol 1985 20: 497–9

    Article  PubMed  CAS  Google Scholar 

  58. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991 Sep; 148(9): 1234–6

    PubMed  CAS  Google Scholar 

  59. Wisner KL, Perel JM. Nortriptyline treatment of breast-feeding women [letter]. Am J Psychiatry 1996; 153: 295

    PubMed  CAS  Google Scholar 

  60. Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patients. Eur J Clin Pharmacol 1988; 35: 217–22

    Article  PubMed  CAS  Google Scholar 

  61. Briggs GG, Samson JH, Ambrose PJ, et al. Excretion of bupropion in breast milk. Ann Pharmacother 1993; 27: 431–3

    PubMed  CAS  Google Scholar 

  62. Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol 1986; 22: 367–70

    Article  PubMed  CAS  Google Scholar 

  63. Illett KF, Hackett LP, Dusci LJ, et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998; 45: 459–62

    Article  Google Scholar 

  64. Hendrick V, Altshuler LL, Wertheimer A, et al. Venlafaxine and breast-feeding. Am J Psychiatry 2001; 158(12): 2089–90

    Article  PubMed  CAS  Google Scholar 

  65. Cohen LS, Viguera AC, Bouffard SM, et al. Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry 2001 Aug; 62(8): 592–6

    Article  PubMed  CAS  Google Scholar 

  66. Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997; 314: 932–6

    Article  PubMed  CAS  Google Scholar 

  67. Stuart S, O’Hara MW. Interpersonal psychotherapy for postpartum depression: a treatment program. J Psychother Pract Res 1995; 4: 18–29

    PubMed  CAS  Google Scholar 

  68. Spinelli MG. Interpersonal psychotherapy for depressed antepartum women: a pilot study. Am J Psychiatry 1997; 154(7): 1028–30

    PubMed  CAS  Google Scholar 

  69. O’Hara MW, Stuart S, Gorman LL, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000; 57: 1039–45

    Article  PubMed  Google Scholar 

  70. Meager I, Milgrom J. Group treatment for postpartum depression; a pilot study. Aust N Z J Psychiatry 1996; 30: 852–60

    Article  PubMed  CAS  Google Scholar 

  71. Morgan M, Matthey S, Barnett B, et al. A group programme for postnatally distressed women and their partners. J Adv Nurs 1997; 26: 913–20

    Article  PubMed  CAS  Google Scholar 

  72. American Psychiatric Association. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. A Task Force Report of the American Psychiatric Association. Washington (DC): American Psychiatric Association, 1990

  73. Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001 Oct; 46: 710–9

    PubMed  CAS  Google Scholar 

  74. Chen Y, Yu SZ, Li WX. Artificial feeding and hospitalization in the first 18 months of life. Pediatrics 1988; 81: 58–62

    PubMed  CAS  Google Scholar 

  75. Riordan JM. The cost of not breastfeeding: a commentary. J Hum Lact 1997; 13: 93–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shaila Misri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Misri, S., Kostaras, X. Benefits and Risks to Mother and Infant of Drug Treatment for Postnatal Depression. Drug-Safety 25, 903–911 (2002). https://doi.org/10.2165/00002018-200225130-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200225130-00002

Keywords

Navigation